You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 4,076,827


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,076,827
Title: Method of treating helminthiasis by parenteral administration of sulfoxide derivatives of benzimidazoles
Abstract:A method is provided for treating or inhibiting helminthiasis by parenterally administering sulfoxide derivatives of benzimidazoles having the structure ##STR1## wherein R.sup.1 is lower alkyl or phenyl-lower alkyl, and R.sup.2 is hydrogen, lower alkyl, halogen, lower alkoxy or nitro. Pharmaceutical compositions for use in the above method are also provided.
Inventor(s): Haugwitz; Rudiger D. (Titusville, NJ), Cruthers; Larry R. (Flemington, NJ)
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Application Number:05/791,828
Patent Claims:1. A method of treating or preventing helminthiasis, which comprises parenterally administering to a mammalian host an effective amount of a compound of the structure ##STR4## wherein R.sup.1 is lower alkyl or phenyl-lower alkyl, R.sup.2 is hydrogen, lower alkyl, lower alkoxy, halogen or nitro dispersed in a non-toxic non-pyrogenic physiologically acceptable carrier.

2. The method as defined in claim 1 where in said compound R.sup.1 is lower alkyl or benzyl.

3. The method as defined in claim 1 where in said compound R.sup.2 is hydrogen.

4. The method as defined in claim 1 wherein said compound has the name [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamic acid, methyl ester.

5. The method as defined in claim 1 wherein said compound is administered subcutaneously.

6. The method as defined in claim 1 wherein said compound is administered intravenously.

7. An injectable composition for use in treating or preventing helminthiasis in mammalian species comprising an effective amount of a compound of the structure ##STR5## wherein R.sup.1 is lower alkyl or phenyl-lower alkyl, R.sup.2 is hydrogen, lower alkyl, lower alkoxy, halogen or nitro, and a non-toxic non-pyrogenic physiologically acceptable carrier therefor selected from the group consisting of sterile water for injection, benzyl benzoate, 1,3-butylene glycol, ethyl oleate, glyceryl triacetate, mixtures thereof and a mixture of benzyl benzoate and sesame oil.

8. The composition as defined in claim 7 wherein said compound has the name [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamic acid, methyl ester.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.